Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Early MS treatment.

M Tintoré1

  • 1Clinical Neuroimmunology Unit, Vall d'Hebron University Hospital, 08035 Barcelona, Spain. mtintore@vhebron.net

International MS Journal
|May 19, 2007
PubMed
Summary
This summary is machine-generated.

Early treatment with disease-modifying drugs is recommended for patients with clinically isolated syndromes or early multiple sclerosis (MS). Prompt treatment, especially with active disease, can positively impact long-term outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic pitfalls and complex cases in MS.

Revue neurologique·2026
Same author

Validation of a New Semiautomated Segmentation Pipeline Based on the Spinal Cord Toolbox DeepSeg Algorithm to Estimate the Cervical Canal Area.

AJNR. American journal of neuroradiology·2023
Same author

[Esclerosis multiple. Lactancia. Lactante. Planificacion familiar. Posparto. Tratamiento modificador de la enfermedad.]

Revista de neurologia·2022
Same author

Consensus statement on the use of alemtuzumab in daily clinical practice in Spain.

Neurologia·2022
Same author

Gadolinium-enhanced brain lesions in multiple sclerosis relapse.

Neurologia·2022
Same author

Leadership in times of crisis. School principals facing COVID-19.

Heliyon·2021
Same journal

American academy of neurology annual meeting.

International MS journal·2011
Same journal

Tumour Necrosis Factor Neutralization in MS: A Cautionary Tale.

International MS journal·2011
Same journal

The clinical usefulness of routine MRI assessment.

International MS journal·2011
Same journal

Acute Psychosis as the Initial Presentation of MS: A Case Report.

International MS journal·2011
Same journal

Russell Brains Review of MS.

International MS journal·2011
Same journal

Epstein-Barr Virus and MS:Causality or Association?

International MS journal·2011
See all related articles

Area of Science:

  • Neurology
  • Immunology

Background:

  • Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Clinically isolated syndromes (CIS) often represent an early stage of MS.
  • Disease-modifying therapies (DMTs) are crucial for managing MS progression.

Purpose of the Study:

  • To evaluate the evidence supporting early initiation of disease-modifying drugs (DMTs) in patients with CIS or early MS.
  • To emphasize the importance of shared decision-making between patients and physicians regarding treatment.

Main Methods:

  • Review of existing research and clinical evidence on early MS treatment.
  • Utilizing magnetic resonance imaging (MRI) to assess disease activity and treatment response.
  • Discussion of the role of biological markers in treatment decisions.

Related Experiment Videos

Main Results:

  • Evidence suggests early treatment in CIS or early MS positively influences long-term disease evolution.
  • Continuing disease activity, confirmed clinically or by MRI, necessitates treatment initiation.
  • MRI is a valuable tool for identifying patients who will benefit most from early DMTs.

Conclusions:

  • Shared decision-making between patients and physicians is essential for initiating early MS treatment.
  • While MRI is useful, further validation of other biomarkers is needed for widespread clinical application.
  • Early intervention in MS can significantly alter the disease's long-term trajectory.